Please login to the form below

Not currently logged in
Email:
Password:

osimertinib

This page shows the latest osimertinib news and features for those working in and with pharma, biotech and healthcare.

Better times ahead, promises AZ as Crestor drop outweighs new drugs

Better times ahead, promises AZ as Crestor drop outweighs new drugs

There were solid gains for lung cancer therapy Tagrisso (osimertinib) and Lynparza (olaparib) for ovarian and latterly breast cancer – up 89% to $338m and 100% to $119m, respectively.

Latest news

More from news
Approximately 5 fully matching, plus 33 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics